2
Apr 2026
Where digital holographic microscopy complements fluorescence microscopy
Integrating Digital Holographic Microscopy with fluorescence techniques enhances live-cell imaging, preserving cellular integrity and improving assay accuracy.
Stay Informed!
2
Apr 2026
AI-powered portable eye scanner makes vision screenings more accessible
Imagine being able to assess how healthy the front of our eyes are not only in hospitals, but also in remote eye-screening camps, elderly-care facilities, pharmacies, or even train stations.
2
Apr 2026
Rising climate pollution may double air quality alerts in the US
Research reveals climate-driven pollution will surge, increasing air quality alerts and highlighting the need for protective actions, especially for seniors.
2
Apr 2026
US scientists sequence 1,000 genomes from measles, a disease long eliminated with vaccines
This week, the Centers for Diseases Control and Prevention posted online its first large tranche of advanced genetic data from measles viruses spreading last year.
2
Apr 2026
State-run insurance plans for foster kids leave some of them without doctors
Ollie Super has moved in and out of cancer treatment since she was diagnosed with neuroblastoma as a toddler in foster care. Now 8, the second grader is dealing with it again. Her cancer came back late last year.
2
Apr 2026
Celiac disease weakens gut microbes that digest fiber
Findings suggest that impaired fiber metabolism in celiac disease is due to microbial deficits, not just diet, emphasizing the need for targeted interventions.
2
Apr 2026
American Heart Association's 9 diet rules to lower heart disease risk
The AHA's dietary guidance emphasizes food choices over fad diets to reduce heart disease risk and improve cardiovascular health across all life stages.
2
Apr 2026
Wegovy® (semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥ 27 kg/m2)
NICE has recommended Wegovy® (semaglutide injection) 2.4 mg as the first GLP-1 RA to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m2).
2
Apr 2026
Wegovy®▼(semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥ 27 kg/m2)
NICE has recommended Wegovy® (semaglutide injection) 2.4 mg as the first GLP-1 RA to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m2).
2
Apr 2026
Wegovy® (semaglutide injection) 2.4 mg recommended by NICE to reduce risk of major adverse cardiovascular events, including heart attacks and strokes, in adults with established cardiovascular disease and overweight or obesity (BMI ≥ 27 kg/m2)
NICE has recommended Wegovy® (semaglutide injection) 2.4 mg as the first GLP-1 RA to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m2).
